Inc. ("Shrink") (OTCBB:INKN), an innovative nanotechnology company developing
products and licensing opportunities in the solar energy production, biotechnology
research and development tools and medical diagnostics businesses, today outlined
key milestones for 2010, which are expected to have a significant impact on
the solar, biotechnology and medical diagnostics industries. The underlying
technology for all the products the company designs, prototypes and manufactures
is a proprietary, patent-pending plastic substrate material called NanoShrink.
And this year, the company is rapidly progressing toward the commercialization
of products and signing agreements with leading manufacturing and distribution
"Our first objective once we developed this revolutionary NanoShrink
technology – because it had so many applications across various industries
– was to determine which sectors had the largest opportunities, offered
the greatest growth potential, and had the biggest return on investment for
all shareholders of Shrink," said Mark L. Baum, CEO of Shrink Nanotechnologies.
"This led us to focus our efforts on the solar, biotechnology and medical
diagnostics industries, where we have the strongest intellectual property protection,
and where we believe we could make a unique and high value-added contribution.
In 2010, we expect to take the innovations we have developed from the lab to
commercialization, where they will help change people’s daily lives."
Shrink is already in various stages of discussions with leading manufacturers
and distributors to bring products in each of its core categories to market
in 2010. Management has received positive feedback from large multi-nationals,
who are looking to collaborate with Shrink on manufacturing, marketing and distribution.
Some of the products being discussed include OptiSol™ (solar technology),
StemDisc™ (biotechnology tools) and MetalFluor™ (medical diagnostics).
*Products on their way to market
The OptiSol Solar Concentrator is a first-of-its-kind nanotechnology-based
plastic solar concentrator and film. Based on electromagnetic non-optical principles,
OptiSol enhances the capabilities and efficiency of existing solar cell designs
by focusing and tuning the incident solar radiation from the sun for optimal
silicon absorption, with less of the total spectrum lost as heat or reflection.
In the second quarter of 2010, the Company expects to unveil an initial working
prototype and discuss its efficiency as well as potential scaled cost per watt
calculation. Because the technology can be easily incorporated into various
residential and commercial construction materials, such as roofing, siding,
and windows, Shrink is working to establish relationships with leading product
design and manufacturing entities in those categories. It expects to have licensing
and joint distribution agreements with strategic manufacturing partners in 2010.
In the biotechnology space, the StemDisc and CellAlign family of products are
an important biotechnology and stem cell research tool for scientists working
to eradicate some of the world’s most medically troubling conditions using
the most leading-edge methods of treatment. One version of StemDisc aids in
embryoid body (EB) formation. It also allows for a multitude of applications
across many currently existing microwell plate formats, thereby increasing the
flexibility of use for researchers. Currently, Shrink is working on an agreement
to develop dyes and molds for scalable commercial quality initial StemDisc devices.
During the first quarter, Shrink expects to provide potential distribution partners
with devices to test and shortly thereafter it expects to begin manufacturing
product and distributing it through a multi-national distributor.
MetalFluor is an innovative technology for the medical diagnostics field that
is designed to inexpensively increase the sensitivity of fluorescence-based
diagnostic tests. Shrink is in discussions to integrate its MetalFluor technology
with existing leading diagnostic sensor platforms, replacing quartz, silicon,
and other glass substrates used in products that measure fluorescent signals.
Shrink’s technology has the potential to greatly increase the sensitivity
of luminescent based assays, enough to allow low-cost light detectors to be
used, enabling more portable instrumentation for point-of-care (POC) testing.
POC applications include environmental and medical (human and animal) diagnostics.